Sienna Biopharmaceuticals
United States

Sienna Biopharmaceuticals, Inc., is a medical dermatology and aesthetics company focused on developing safe and effective targeted therapies to treat inflammatory skin conditions and aesthetic concerns that impact the health and appearance of patients.

Sienna is led by a team of accomplished scientists, clinicians and business leaders who have developed and commercialized leading global brands in dermatology and aesthetics. Sienna is building an innovative, diversified pipeline to address unmet needs in medical dermatology and aesthetics.

The company's lead candidate, SNA-1120, is in Phase IIb testing to treat pruritus and psoriasis. SNA-120 is a topical neurotrophic tyrosine kinase receptor 1 inhibitor. Sienna is also developing SNA-125 for atopic dermatitis, psoriasis and pruritus. Both drug candidates were obtained via its December 2016 acquisition of Creabilis plc.



Status: Realised